Connect with us

Covid

Covid-19 second wave: Precautions for pregnant women

Published

on

Covid-19 second wave: Precautions for pregnant women

We already know that surviving the deadly coronavirus is difficult and it becomes extremely hard when you are with a child. So, we have some useful notes for all the pregnant women out there. Give a quick read because these are important.

1. Asymptomatic and mild disease during pregnancy-

In more than 95% pregnant women there are no complications except more chances of cesarean delivery and psychological disturbances, anxiety and depression.

Fetus and neonates are not affected approximately 4% to 6% chances of a newborn becoming positive.

Newborn to be isolated from mother but breast feeding to be continued even when mother is positive. Breast milk and skin-to-skin contact are safe in Covid-19 infected mothers if performed with appropriate use of precautions such as hand and breast hygiene and masking.

Also there is no effect on the fetus and mother when mild to moderate Covid infection occurs during early pregnancy. It is not an indication for the medical termination (abortion).

There is no data suggesting vaginal delivery increases chances of neonatal infections.

2. Moderate to severe or acute respiratory disease or patients with comorbidities

Chances of preeclampsia, intrauterine growth retardation and premature delivery increase 4 to 5 times
Chances of fetal or mother’s death increase chances of postpartum hemorrhage and blood transfusion increase if a patient delivers during active Covid infection.

Cesarean section rates are very high to avoid nosocomial infection of newborn and improve perinatal outcome.

Amniotic fluid, placenta, cord blood and newborn blood have 4 to 6% chances of active viral load in all Covid positive mothers.

3. Vaccines for pregnant and lactating mothers are not recommended in India. (Based on how these vaccines work in the body, experts believe they are unlikely to pose a specific risk for people who are pregnant. However, there are currently limited data on the safety of Covid-19 vaccines in pregnant people. Clinical traits that look at the safety and how well the Covid-19 vaccines work in pregnant people are underway or planned. Vaccine manufacturers are also monitoring data from people in the clinical traits who received vaccine and became pregnant. Studies in animals receiving a Moderna, Pfizer-BioNTech or Johnson & Johnson’s Janssen (J&J/Janssen) Covid-19 vaccine before or during pregnancy found no safety concerns.

Protection of Covid affected mother’s antibodies to newborn is not yet confirmed.

Mother’s or child’s blood group relationship with severity of disease not confirmed.

4. Treatment protocol does not change because of pregnancy status.

5. Indirect effects of lockdown or non-availability of doctors or hospital beds have made significant negative impact on ante-natal, intra-natal and post-natal care in many countries resulting in negative outcomes for mother and child as well.

– By Jagdip Shah, M.D., D.G.O. Obstetrician & Gynecologist with 36 years of experience & practicing in Mumbai since 1984.

Covid

Covaxin protects recipients from severe Covid-19: Researchers

Published

on

By

Covaxin protects recipients from severe Covid-19: Researchers

According to the researchers, India’s Covaxin activates key memory components of the human immune system that can continue to protect recipients from severe Covid-19 even after the vaccine-generated anti-viral antibodies have waned.

“We see amazingly robust immune memory responses very similar to those caused by the natural infection,” said Nimesh Gupta, a scientist at the National Institute of Immunology (NII), New Delhi, who led the study.

“These memory responses will outlast and confer protection even the concentrations of the initial antibodies deplete over months,” Gupta said.

Continue Reading

Covid

Covid-19 in India: 8,488 new Covid cases in last 24 hours, lowest in 538 days

Published

on

By

On Monday, India reported 8,488 new cases over the previous 24 hours, 19.1% lower than Sunday’s statistics. This was the lowest in 538 days.

With this, country’s cumulative caseload to 3,45,18,901. The number of active cases now stands at 1,18,443 — the lowest in 534 days.

As per the Health Ministry data, as many as 12,510 recoveries were recorded on Monday over the previous 24 hours while the number of deaths stood at 249, taking the total toll to 4,65,911.

The top five states that registered the maximum cases were Kerala with 5,080 cases, followed by Tamil Nadu with 756 cases, West Bengal with 727 cases, Maharashtra with 298 cases, and Karnataka with 247 cases. As much as 83.75% of the new cases were reported from these five states.

Continue Reading

Covid

Covaxin 77.8% effective against Covid-19

Published

on

By

Covaxin 77.8% effective against Covid-19

Medical journal Lancet has now stated that the made-in-India vaccine is 77.8 per cent effective against symptomatic Covid, as demonstrated by the phase 3 data. This came out after the World Health Organisation (WHO) approved Bharat Biotech’s Covaxin for emergency use.

The efficacy data demonstrated 70.8 per cent protection against all variants of the SARS-CoV-2 virus.

As per the phase 3 data, Covaxin was found to be 65.2 per cent effective against the Delta variant, 93.4 per cent effective against severe symptomatic Covid and 63.6 per cent effective against asymptomatic Covid.

Dr. Krishna Ella, CMD of Bharat Biotech said, “The peer-review of Covaxin phase III clinical trial data in The Lancet, an authoritative voice in global medicine, validates our commitment to data transparency and meeting the stringent peer-review standards of world-leading medical journals. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, Indian Council of Medical Research, National Institute of Virology, and the trust imposed by our trial participants who made this happen.”

Continue Reading

Trending